Personalized Cancer Vaccines Market Growth 2024-2031: Driven by Rising Cancer Incidence

Personalized Cancer Vaccines

The Global Personalized Cancer Vaccines Market is expected to grow at a high CAGR during the forecast period (2024-2031).

The Personalized Cancer Vaccines Market focuses on developing vaccines tailored to an individual’s  growth profile using advanced technologies like next-generation sequencing (NGS), artificial intelligence (AI), and mRNA platforms. These vaccines enhance the immune system’s ability to recognize and attack cancer cells more effectively.

rising cancer prevalence, advancements in immunotherapy, and increasing investments in precision medicine driving the market growth of Personalized Cancer Vaccines. With continued advancements, personalized cancer vaccines are set to transform cancer treatment, offering more targeted and effective therapies.

Download Free Sample PDF:  https://www.datamintelligence.com/download-sample/personalized-cancer-vaccines-market

Market Growth Drivers:

Rising Cancer Cases around the globe are accelerating the growth of the Personalized Cancer Vaccines Market.

The Personalized Cancer Vaccines Market is expanding as cancer cases rise globally. The American Cancer Society reported 89,500 cases in the U.S. in 2020, while the IARC projects 27.5 million new cases worldwide by 2040. With the growing demand for advanced therapies, the adoption of personalized cancer vaccines is on the rise.

The high costs associated with treatments are expected to limit the growth of the global Personalized Cancer Vaccines market.

According to a study published by BMC Health Services on June 3, 2020, the cost of genomic sequencing for cancer control varies significantly. For example, targeted panels cost between $240 and $29, exome sequencing ranges from $604 to $1,932, and whole-genome sequencing can cost between $2,006 and $3,347 per person. These high costs are a key factor slowing down market growth.

Market Segments: 

By Cancer Type the market is classified into Cervical Cancer, Prostate Cancer, Glioblastoma, Others

On the basis By Vaccine Type the market is sub-segmented as Peptide-based Vaccine, Dendritic Cell Vaccine, DNA & RNA Vaccine, Others

By End-User the market is bifurcated into Hospitals, Cancer research centers, Clinics, Others

By Region the market is divided into North America, Europe, South America, Asia Pacific, Middle East, and Africa

Prostate cancer

Prostate cancer is a significant health concern, with an estimated 1.41 million cases reported worldwide in 2020, according to the WHO. For example, the National Cancer Institute (NCI) is conducting Phase 1/2 trials to evaluate the safety and effectiveness of PROSTVAC, a therapeutic cancer vaccine, combined with Nivolumab (an anti-PD-1 therapy) for men with prostate cancer.

Dendritic Cell Vaccines

Monocytes are extracted from a patient’s blood and cultured with synthetic neoantigens to create mature dendritic cells. These are then reinfused back into the patient’s bloodstream. For example, a phase 1 trial by the University of Pennsylvania is investigating the use of dendritic cells as a vaccine to stimulate the immune system to target melanoma cells, followed by pembrolizumab treatment.

For instance, a Phase 3 trial is underway to evaluate the bivalent HPV vaccine, Cecolin®, in alternate 2-dose regimens, comparing it to the established HPV vaccine, Gardasil® (FDA-approved for cervical cancer in 2006). This study is being conducted by PATH Global Health in collaboration with Leidos Biomedical Research, Inc., Emmes Company, LLC, and Biotech Co., Ltd.

Competitive Landscape

  • Genocea Biosciences Inc.
  • Advaxis Inc 
  • BioNtech S E
  • Celldex Therapeutics
  • Bristol-Myers Squibb
  • Genentech
  • Gritstone Oncology
  • Merck & Co
  • Moderna Therapeutics
  • Neon Therapeutics. 

Customize Your Scope: https://www.datamintelligence.com/customize/personalized-cancer-vaccines-market

Regional Growth

North America leads the global cancer stem cells market, driven by a high cancer incidence and strong R&D efforts. According to the IARC, 13 million new cancer cases occur worldwide. The region benefits from FDA approvals of new drugs and a large number of organizations dedicated to advancing cancer vaccine research.

Asia Pacific is set to be the fastest-growing market, driven by rising cancer cases, a growing focus on preventive care, and government-backed technological innovations. Notably, Henan Cancer Hospital is conducting a Phase I trial of a Tumor Neoantigen Vaccine to advance cancer treatment.

Key developments:

BioNTech, in collaboration with Sanofi, is studying SAR441000 (BNT131) in a Phase 1 clinical trial. The trial explores its use as a monotherapy for patients with advanced melanoma and in combination with an anti-PD-1/PD-L1 checkpoint inhibitor for patients with advanced melanoma and other solid tumors.

DataM Intelligence

DataM Intelligence

DataM Intelligence is approved by the Newstrail editorial board to provide critical insights. The group represents researchers specializing in global market trends, competitive landscapes, and emerging sector developments. Their work spans healthcare, technology, and industrial sectors, focusing on data-driven insights to help organizations make informed strategic decisions.